Cargando…

SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE

INTRODUCTION: Therapeutic options for metastatic paraganglioma (PGL) are limited, especially in the presence of uncontrolled secondary hypertension (HTN). Early findings from Lutetium-177 (Lu-177) DOTATE show promise for efficacy, although data on HTN control and survival are uncertain. Herein, we p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erturk, Banu, Tuncel, Murat, Orhan, Diclehan, Turer, Ozlem Bozbeyi, Dizdar, Omer, Sendur, Suleyman Nahit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653190/ http://dx.doi.org/10.1210/jcemcr/luac014.003

Ejemplares similares

MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2020)

MON-196 A Single-Center Experience of Patients with Metastatic Pheochromocytoma/Paraganglioma Treated with (177)Lu-DOTATATE
por: Roslyakova, Anna, et al.
Publicado: (2020)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

How the algorithms can change during the COVID-19 pandemic: A case of primary hyperaldosteronism
por: Iremli, Burcin Gonul, et al.
Publicado: (2023)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Management of SHDB positive patient with metastatic bilateral giant retroperitoneal paragangliomas
por: Strauss, David, et al.
Publicado: (2021)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020)

SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy
por: Gubbi, Sriram, et al.
Publicado: (2020)

A Rare Case of a Right Atrial Paraganglioma in an Individual with the SHDB Mutation
por: Lancaster, Ian, et al.
Publicado: (2022)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

Software-assisted dosimetry in peptide receptor radionuclide therapy with (177)Lutetium-DOTATATE for various imaging scenarios
por: Kupitz, Dennis, et al.
Publicado: (2017)

Mutational Profile of Metastatic Pheochromocytoma and Paraganglioma
por: Choi, Yun Mi, et al.
Publicado: (2021)

MON-398 Clinical Case Of Retroperitoneal Paraganglioma
por: Davidenko, Ilia, et al.
Publicado: (2019)

SAT-216 Retroperitoneal Paraganglioma: Case Report
por: Silva, Eugénia Morado, et al.
Publicado: (2020)

MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)

MON-384 The Dynamic Genetics of Recurrent Paragangliomas: The Importance of Surveillance
por: Taha, Reem, et al.
Publicado: (2019)

SAT-195 The Diagnosis and Management of a Functional Paravertebral Paraganglioma
por: Findlay, Ryan, et al.
Publicado: (2020)

MON-218 Clinical and Genetic Aspects of Pediatric Pheochromocytomas and Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

MON-204 Pheochromocytoma and Paraganglioma: An Emerging Cause of Secondary Osteoporosis
por: Yokomoto-Umakoshi, Maki, et al.
Publicado: (2020)

MON-LB040 Challenge in Diagnosing and Treating of Mediastinal Paraganglioma
por: Alomair, Basil, et al.
Publicado: (2020)

Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma
por: Vanova, Katerina Hadrava, et al.
Publicado: (2021)

Malignant Testicular Paraganglioma: The Importance of Adequate Clinical Follow-Up
por: Alves Pantaleão, Priscilla Maris Pereira, et al.
Publicado: (2021)

Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
por: Smith-Palmer, J., et al.
Publicado: (2021)

SAT-191 A Case of Hypoplastic Left Heart Syndrome and Paraganglioma
por: Bowes, Christa, et al.
Publicado: (2020)

A Multifocal Paraganglioma in an African Male Due to an Underlying SDHB Mutation
por: Siddiqui, Nida Mishraz, et al.
Publicado: (2021)

PSAT027 An Incidentally-Discovered Retro-Cardiac Paraganglioma Presenting as NSTEMI
por: Bal, Simrun, et al.
Publicado: (2022)

ODP041 Hearing Loss Reveals Dopamine-secreting Metastatic Paraganglioma
por: Cutrone, Lauren S, et al.
Publicado: (2022)

ODP032 Case Series: Prazosin in the Preoperative Management of Pheochromocytoma and Paraganglioma
por: Barreiro, Margarita, et al.
Publicado: (2022)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

MON-177 CAH-X Syndrome in a German Cohort of Patients with Congenital Adrenal Hyperplasia
por: Sappl, Andrea, et al.
Publicado: (2020)

SUN-344 SDHB Immunostaining: Still an Indispensable Tool in Characterising Pheochromocytoma and Paraganglioma
por: Velusamy, Anand, et al.
Publicado: (2019)

Transaminitis Evaluation Leads to the Incidental Diagnosis of Familial Paraganglioma Due to SDHB Mutation
por: Okafor, Anderson, et al.
Publicado: (2021)

RF33 | PSUN03 Rates of Pheochromocytoma/Paraganglioma Screening in At-Risk Populations
por: Grigoryan, Seda, et al.
Publicado: (2022)

Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
por: Zhang, Vivian, et al.
Publicado: (2023)

MON-377 Hereditary Paraganglioma Pheochromocytoma Syndrome in the Setting of End Stage Renal Disease
por: Harty, Roger
Publicado: (2019)

OR29-4 Pregnancy Outcomes in Women with Pheochromocytoma and Paraganglioma: An International Multi-Center Study
por: Bancos, Irina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tdu1i0uhku8u47an3hl5fdl56u